Back to Agenda
Session 2 Hot Topics for QPPV Oversight
Session Chair(s)
Vicki Edwards, RPh
Vice President, Pharmacovigilance Excellence and International QPPV, Abbvie, United Kingdom
Post the new legislation implementation we are still in a time of change whereby new GVPs and guidance documents are released and existing documents are updated. The industry continues to engage with the Regulators to provide feedback on the changes and new requirements on practical implications and opportunities for clarifications and potential improvements. Not all companies are represented on the various trade associations that form the main forum for ongoing discussion with Regulators and so this session will share the topics of interest currently under discussion.
Speaker(s)
Brexit
Vicki Edwards, RPh
Vice President, Pharmacovigilance Excellence and International QPPV, Abbvie, United Kingdom
Medical Literature Monitoring
John Barber
QPPV and Director, Head of Pharmacovigilance, European Operations, Dr. Reddy's Laboratories (UK) Ltd., United Kingdom
Reference Safety Information
Esteban Herrero-Martinez, PhD
Director Regulatory Policy and Intelligence, Novartis Pharmaceuticals UK Limited, United Kingdom
Module V
Guy Demol
EU QPPV, MSD, Belgium
Off-label Use
Michael Richardson, MD, FFPM, FRCP
Senior Vice President, WorldWide Patient Safety , Bristol-Myers Squibb, United Kingdom
Module IX
Kristina Strutt, MD, MA, MRCP, FFPM
Senior Vice President, Ipsen Biopharm Limited, United Kingdom
Biologics
Sue Rees, MS
Director , Sue Rees Consultancy Ltd, United Kingdom
Module VI
Peter De Veene, MD
QPPV, MSD Belgium, Belgium
Have an account?